业绩回顾1Q25 业绩符合我们预期公司公布1Q25 业绩：收入5.26 亿元，同比增长59.17%；归母净利润亏损2.54 亿元，同比减亏接近1 亿元，符合我们预期。发展趋势产品收入保持同比亮眼增长，经营现金流改善良好。1Q25 公司收入同比增长59.17%，我们估计泰它西普和维迪西妥单抗销量均有较好增长。研发费用3.29 亿元，同比基本持平，得益于收入增加，研发费用率62.53%，同比下降...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.